US2015366794A1PendingUtilityA1

Use of bethanechol for treatment of xerostomia

48
Assignee: ACACIA PHARMA LTDPriority: Nov 12, 2009Filed: Sep 1, 2015Published: Dec 24, 2015
Est. expiryNov 12, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Inventors:Nicola CooperJulian Clive GilbertRobert William GristwoodMichael Wyllie
A61P 43/00A61P 1/02A61P 1/00A61K 9/08A61K 9/006A61K 45/06A61K 31/27A61K 9/0056
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Bethanecol is administered topically, for the treatment of xerostomia.

Claims

exact text as granted — not AI-modified
1 . A method of treating xerostomia, comprising buccal administration of bethanechol to a subject in need thereof. 
     
     
         2 . The method of  claim 1 , wherein the xerostomia is associated with head and neck cancer. 
     
     
         3 . The method of  claim 1 , wherein the xerostomia is associated with drug treatment. 
     
     
         4 . The method of  claim 1 , wherein the xerostomia is associated with cancer chemotherapy treatment. 
     
     
         5 . The method of  claim 1 , wherein the xerostomia is associated with Sjogren's syndrome. 
     
     
         6 . The method of  claim 1 , wherein the xerostomia is associated with late-stage cancer. 
     
     
         7 . The method of  claim 1 , wherein the bethanechol is in the form of bethanechol chloride. 
     
     
         8 . The method of  claim 1 , wherein the bethanechol is in the form of the S-enantiomer. 
     
     
         9 . The method of  claim 1 , wherein the bethanechol is maintained in the buccal cavity for between 30 seconds to 5 minutes. 
     
     
         10 . The method of  claim 9 , wherein the bethanechol is maintained in the buccal cavity for between 1 minute to 3 minutes. 
     
     
         11 . The method of  claim 9 , wherein the bethanechol is maintained in the buccal cavity for 2 minutes. 
     
     
         12 . The method of  claim 1 , wherein the bethanechol is swallowed. 
     
     
         13 . The method of  claim 1 , wherein the bethanechol is maintained in the buccal cavity for between 30 seconds to 5 minutes and is then swallowed. 
     
     
         14 . The method of  claim 1 , wherein the bethanechol is maintained in the buccal cavity for between 1 minute to 3 minutes and is then swallowed. 
     
     
         15 . The method of  claim 1 , wherein the bethanechol is maintained in the buccal cavity for 2 minutes and is then swallowed. 
     
     
         16 . The method of  claim 1 , wherein the bethanechol is administered more than once daily. 
     
     
         17 . A buccal formulation of bethanechol, comprising bethanechol in the amount of between 2 mg and 25 mg in a solution or semi-solid formulation of between 0.1 ml and 1.0 ml. 
     
     
         18 . The buccal formulation of  claim 17 , further comprising a preservative. 
     
     
         19 . The buccal formulation of  claim 17 , wherein the formulation is sterile.

Join the waitlist — get patent alerts

Track US2015366794A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.